All AbMole products are for research use only, cannot be used for human consumption.

Meropenem is an ultra-broad spectrum injectable antibiotic. Meropenem inhibits bacterial wall synthesis like other beta-lactam antibiotics. In contrast to other beta-lactams, meropenem is highly resistant to degradation by beta-lactamases or cephalosporinases.
Microbiol Immunol. 2023 Jul 4.
Analysis of multidrug‐resistant determinants of clinically isolated Acinetobacter baumannii CYZ via whole genome sequencing
Meropenem purchased from AbMole
| Molecular Weight | 383.46 |
| Formula | C17H25N3O5S |
| CAS Number | 96036-03-2 |
| Solubility (25°C) | DMSO 70 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[3] Sohita Dhillon. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
| Related Antibiotic Products |
|---|
| Amphotericin B Solubilized
Amphotericin B Solubilized is a powdery form composed of amphotericin sodium deoxycholate and a buffer. This special design enables amphotericin B can be completely dissolved in aqueous solution. |
| Hydroxy Itraconazole
Itraconazole metabolite Hydroxy Itraconazole is an active metabolite of Itraconazole (ITZ), which is a triazole antifungal agent. |
| Marbofloxacin
Marbofloxacin is a potent antibiotic of the 3rd generation fluoroquinolone group which inhibiting bacterial DNA replication. |
| Linezolid
Linezolid (PNU-100766) is a synthetic antibiotic. Linezolid acts by inhibiting the initiation of bacterial protein synthesis. |
| Daptomycin
Daptomycin is the first member of a new class of bactericidal antibiotics, the cyclic lipopeptides. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
